Search

Your search keyword '"Calistri, E."' showing total 2 results
Start Over Author "Calistri, E." Publisher ferrata storti foundation
2 results on '"Calistri, E."'

1. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.

Author

Bonifacio M, Binotto G, Maino E, Calistri E, Marin L, Scaffidi L, Frison L, De Marchi F, Krampera M, Semenzato G, Fanin R, Ambrosetti A, and Tiribelli M

Subjects
Chromosome Aberrations, Fusion Proteins, bcr-abl genetics, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Retrospective Studies, Time Factors, Treatment Outcome, Antineoplastic Agents therapeutic use, Imatinib Mesylate therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Protein Kinase Inhibitors therapeutic use
Published
2015
Full Text
View/download PDF

2. The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype.

Author

Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A, Cavallin M, and Fanin R

Subjects
ATP Binding Cassette Transporter, Subfamily G, Member 2, Acute Disease, Adult, Antigens, CD genetics, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Female, Humans, Karyotyping, Leukemia, Myeloid drug therapy, Prognosis, Reference Values, Retrospective Studies, ATP Binding Cassette Transporter, Subfamily B, Member 1 genetics, ATP-Binding Cassette Transporters genetics, Drug Resistance, Multiple, Leukemia, Myeloid genetics, Neoplasm Proteins genetics
Abstract

Multidrug resistance is a major cause of treatment failure in acute myeloid leukemia (AML). P-glycoprotein (PGP) over-expression has an unfavorable prognostic significance, while the role of breast cancer resistance protein (BCRP) is less clear, especially in AML patients with a normal karyotype. We studied 73 consecutive AML patients with a normal karyotype. BCRP was over-expressed in 24 patients (33%) and was significantly co-expressed with PGP (13/24 vs 11/49, p=0.006) and with CD56. Only PGP, along with age and CD34, affected the achievement of complete remission (p=0.02), while BCRP-positive cases showed an increased risk of relapse (p=0.005) and a shorter disease-free survival (p=0.027). BCRP over-expression did not influence the achievement of remission, but significantly affected the duration of complete remissions. BCRP may, therefore, be regarded as a prognostic factor in patients with normal karyotype AML, for the design of risk-adapted post-remission therapy.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results